ROS1 and lung carcinoma: Here we analyzed the genomic landscape of two pre-mortem and 11 post-mortem metastatic tumors collected from an advanced, <i>ROS1</i> fusion-positive lung cancer patient, who had received sequential ROS1 inhibitors.